Changes in hemoglobin and clinical outcomes drive improvements in fatigue, quality of life, and physical function in patients with paroxysmal nocturnal hemoglobinuria: post hoc analyses from the phase III PEGASUS study

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, chronic, acquired, hematologic, life-threatening disease characterized by thrombosis, impaired bone marrow function, and complement-mediated hemolysis. The PEGASUS phase III clinical trial demonstrated superiority of pegcetacoplan over eculizumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Cella, David, Sarda, Sujata P., Hsieh, Ray, Fishman, Jesse, Hakimi, Zalmai, Hoffman, Kate, Al-Adhami, Mohammed, Nazir, Jameel, Cutts, Katelyn, Lenderking, William R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375756/
https://www.ncbi.nlm.nih.gov/pubmed/35869984
http://dx.doi.org/10.1007/s00277-022-04887-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375756/
https://www.ncbi.nlm.nih.gov/pubmed/35869984
http://dx.doi.org/10.1007/s00277-022-04887-8

Ejemplares similares